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Substrate speciﬁcity studiesDespite the importance of neuraminidase (NA) activity in effective infection by inﬂuenza A viruses, limited
information exists about the differences of substrate preferences of viral neuraminidases from different hosts
or from different strains. Using a high-throughput screening format and a library of twenty α2–3- or α2–6-
linked para-nitrophenol-tagged sialylgalactosides, substrate speciﬁcity of NAs on thirty-seven strains of
human and avian inﬂuenza A viruses was studied using intact viral particles. Neuraminidases of all viruses
tested cleaved both α2–3- and α2–6-linked sialosides but preferred α2–3-linked ones and the activity was
dependent on the terminal sialic acid structure. In contrast to NAs of other subtypes of inﬂuenza A viruses
which did not cleave 2‐keto‐3‐deoxy‐D-glycero-D-galacto-nonulosonic acid (Kdn) or 5-deoxy Kdn (5d-Kdn),
NAs of all N7 subtype viruses tested had noticeable hydrolytic activities on α2–3-linked sialosides containing
Kdn or 5d-Kdn. Additionally, group 1 NAs showed efﬁcient activity in cleaving N-azidoacetylneuraminic acid
from α2–3-linked sialoside.h Center, Shandong University,
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Human inﬂuenza A virus is an important pathogen that causes an
acute viral disease of the respiratory tract in millions of people each
year. Avian inﬂuenza A virus outbreaks have caused major losses for
the poultry industry (Spicuzza et al., 2007), but can also cause deadly
diseases (e.g. H5N1) as well as less severe infections in humans
(Swayne and Halvorson, 2008). The 2009 pandemic by an inﬂuenza A
virus strain of mixed avian and swine origins have stimulated
renewed interest into emerging inﬂuenza virus strains.
Inﬂuenza A virions contain two types of surface glycoproteins,
hemagglutinin (HA) and neuraminidase (NA), both recognizing sialic
acid-containing receptors on the host cell surface. HAs bind to cell
surface sialyloligosaccharides and mediate the entry of the virus into
the cell (Wiley and Skehel, 1987). NAs are believed to prevent the
aggregation of progeny virions by removing sialic acid from the
carbohydrate moieties of newly synthesized HA and NA glycopoly-
peptides (Palese et al., 1974) and facilitate the spreading of progenyvirions by removal of sialic acid from the glycoconjugates on the
surface of infected host cells (von Itzstein, 2007). Recent studies found
that in addition to its previously recognized functions, NA plays a
direct and early role in inﬂuenza A virus entry into host target cells.
The presence of NA signiﬁcantly enhanced both pseudotype infectiv-
ity and cell–cell fusion (Su et al., 2009). Therefore, understanding the
substrate speciﬁcity of inﬂuenza A virus NAs is critical for preventing
direct transmission of virus from avian or other species to human and
for developing new potent NA inhibitors.
Neuraminidases (EC 3.2.1.18) are sialoside hydrolyzing enzymes
which cleave the glycosidic linkages between the terminal sialic
acid and an adjacent sugar residue. To date, studies on the substrate
speciﬁcity of inﬂuenza A virus neuraminidases are limited to a small
number of inﬂuenza strains and a restricted set of sialosides. The NAs
of N2 inﬂuenza A viruses isolated from different hosts were shown to
differ in their ability to distinguish α2–3-linked and α2–6-linked
sialyl lactose (Baum and Paulson, 1991; Couceiro and Baum, 1994;
Franca de Barros et al., 2003; Kobasa et al., 1999). The recognition of
underlying glycan structures of sialosides by human inﬂuenza A
viruses has been observed (Katinger et al., 2004). More recently, the
substrate speciﬁcity of the neuraminidases of H1N1 inﬂuenza A virus
and avian-human reassortant inﬂuenza A viruses were studied using
six sialosides, including BODIPY-labeled α2–3-linked sialyl lactose,
α2–3-linked sialyl N-acetyllactosamine, sialyl Lewis c, sialyl Lewis a,
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mine (Mochalova et al., 2007; Shtyrya et al., 2009). Most NAs used for
these substrate speciﬁcity studies were either recombinant enzymes
or expressed by puriﬁed viruses.
Here, we report on a substrate speciﬁcity study of NAs on thirty-
seven human and avian inﬂuenza A viruses using gradient puriﬁed
and/or non-puriﬁed viral particles conducted by employing a high-
throughput screening format using a library of twentyα2–3- orα2–6-
linked para-nitrophenol-tagged sialyl galactosides Siaα2–3/6GalβpNP
synthesized by a highly efﬁcient one-pot three-enzyme system (Cao
et al., 2009). This proof-of-principle study demonstrates that the
obtained information can be used to design novel neuraminidase
inhibitors that target a select group of NAs on inﬂuenza A viruses.
Results
Viruses analysis
As shown in Table 1, thirty-seven viral strains were used in this
study. Among these viral strains, twenty-two were avian-origin
inﬂuenza A viruses isolated from free-ﬂying wild birds or domestic
captive birds in different locations of California and at various times
(1996, 1998, 2006, 2005, 2007, 2008) with different hemagglutinin
(belonging to group 1 hemagglutinin H1, H5, H6, H12 or group 2
hemagglutinin H3, H4, H10) and neuraminidase subtypes (belonging
to group 1 neuraminidase N1, N5, N8 or group 2 neuraminidase N2,
N6, N7, and N9); ten were avian H9N2 subtype inﬂuenza A virusesTable 1
Inﬂuenza A viruses used in this study.
Viral strain
Avian inﬂuenza A viruses
N1 A/northern shoveler/California/HKWF569/2007
A/northern shoveler/California/HKWF216/2007
A/mallard/California/8212/2008
A/mallard/ California/8322/2008
A/green winged teal/California/8326/2008
N2 A/northern shoveler/California/HKWF268/2007
A/green winged teal/California/7972/2008
A/mallard/California/8035/2008
N5 A/american wigeon/California/HKWF295/2007
A/american wigeon/California/HKWF541/2007
A/american wigeon/California/8352/2008
N6 A/env/California/7896/2008
N7 A/emu/California/2092/1996
A/northern shoveler/California/JN950/2006
A/greater white-fronted
goose/California/HKWF446/2007
A/northern shoveler/California/HKWF848/2007
A/northern shoveler/California/HKWF1021/200
A/northern shoveler/California/HKWF1128/200
A/cinnamon teal/California/HKWF1111/2007
A/mallard/California/6957/2008
N8 A/ring-necked duck/California/K90/2005
N9 A/green winged teal/California/8204/2008
H9N2 avian A/duck//Hong Kong/448/1978
A/duck/Hong Kong/702/1979
A/quail/Hong Kong/A28945/1988
A/quail/Arkansas/29209-1/1993
A/duck/Hong Kong/Y280/1997
A/chicken/Hong Kong/G9/1997
A/pheasant/California/2373/1998
A/chicken/Hong Kong/SF3/1999
A/duck/Hong Kong/702/1979-quail adapted23
A/duck/Hong Kong/702/1979-chicken adaptedA
H9N2 humana A/Hong Kong/2108/2003 (H9N2)
Human inﬂuenza A virusesa
N1 A/Puerto Rico/34/8
A/Memphis/71
N2 A/Udorn/307/72
A/Philippines/2/82/X-79
a Human inﬂuenza A viruses are shown in italics.either isolated from domestic birds in Hong Kong in different years
(1978, 1979, 1988, 1993, 1997, 1998, 1999) or isolated from duck in
Hong Kong in 1979 and adapted to quail or chicken; one was a human
H9N2 inﬂuenza A virus HK/2108/03 isolated in 2003; and four
were human inﬂuenza A viruses belonging to H1N1, H3N1 and H3N2.
Among human inﬂuenza A viruses, A/Memphis71 is a reassortant
carrying the hemagglutinin of A/Memphis/1/71 (H3) and the neur-
aminidase of A/Bellamy/42 (N1). H9N2 avian inﬂuenza A viruses
from birds with demonstrated adaptation to mammals (Wan et al.,
2008; Xing et al., 2011) were classiﬁed into a separate group in order
to test the effect of the adaptation and interspecies transmission of
viruses from avian to mammalian species on the substrate speciﬁcity
of neuraminidase.
Substrate speciﬁcity of neuraminidases from avian and H9N2 inﬂuenza
viruses
Using twenty α2–3- and α2–6-linked sialyl galactosides including
Siaα2–3/6GalβpNP containing N-acetylneuraminic acid (Neu5Ac), N-
glycolylneuraminic acid (Neu5Gc), 2‐keto‐3‐deoxy‐D-glycero-D-
galacto-nonulosonic acid (Kdn), or their C5-derivatives (Table 2)
(Cao et al., 2009), a substrate speciﬁcity study of neuraminidases
from different strains of viruses all normalized to the same HA-titer
shows important similarities and differences (Table 3 and Fig. S1)
All inﬂuenza A viruses tested have relatively good sialic acid
cleavage activities towards α2–3-linked sialosides Neu5Acα2–
3GalβpNP (compound 1a), Neu5AcFα2–3GalβpNP (compound 2a),Type Abbreviation
H3N1 sh/HKWF569/07
H6N1 sh/HKWF216/07
H6N1 mal/8212/08
H6N1 mal/8322/08
H1N1 tel8326/08
H6N2 sh/HKWF268/07
H6N2 tel/7972/08
H5N2 mal/8035/08
H6N5 wi/HKWF295/07
H6N5 wi/HKWF541/07
H12N5 wi/8352/08
H4N6 dk/7896/08
H10N7 emu/2092/96
H10N7 sh/JN950/06
H10N7 gos/HKWF446/07
H3N7 sh/HKWF848/07
7 H3N7 sh/HKWF1021/07
7 H2N7 sh/HKWF1128/07
H5N7 tel/HKWF1111/07
H10N7 mal/6957/08
H6N8 dk/K90/05
H5N9 tel/8204/08
H9N2 dk/448/78
H9N2 dk/702/79
H9N2 Q/A28945/88
H9N2 Q/29209-1/93
H9N2 dk/Y280/97
H9N2 ck/G9/97
pt/2373/98
H9N2 ck/SF3/99
H9N2 QA23
10 H9N2 Qa23CkA10
H9N2 HK/2108/03
H1N1 A/PR8
H3N1 A/Mem71
H3N2 A/Udorn72
H3N2 A/Philips
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mallard/California/8035/2008 (H5N2), A/green winged teal/California/
8204/2008 (H5N9), A/Quail/HongKong/A28945/1988 (H9N2), A/Duck/
Hong Kong/Y280/1997 (H9N2), A/Chicken/Hong Kong/G9/1997
(H9N2)] have weaker neuraminidase activities than others as shown
by different absorption maxima indicated in the graphs (Fig. S1). All
viruses tested have higher activity towards α2–3-linked sialosides
(compounds 1a–10a) than α2–6-linked sialosides (compounds 1b–
10b). Neu5Acα2–3GalβpNP (compound 1a) is the best substrate for all
viruses tested. In contrast, α2–3- or α2–6-linked sialosides containingTable 2
Structures of para-nitrophenol-tagged α2–3- and α2–6-linked sialyl galactosides Siaα2–3
speciﬁcity studies of neuraminidases on the surface of viral particles.
Number Compounds
1a − 10a Siaα2 − 3GalβpNP
1b − 10b Siaα2 − 6GalβpNP
Sialic acid name 
1a or 1b Neu5Ac (R= NHAc) 
2a or 2b Neu5AcF (R= NHCOCH2F) 
3a or 3b Neu5AcOMe (R= NHCOCH2OMe) 
4a or 4b Neu5AcN3 (R= NHCOCH2N3)
5a or 5b Neu5Gc (R= NHCOCH2OH) 
6a or 6b 5d − Kdn (R= H)
7a or 7b 5F − Kdn (R= F)
8a or 8b 5Me − Kdn (R= OMe)
9a or 9b 5N3 − Kdn (R= N3)
10a or 10b Kdn (R= OH) C5-OMemodiﬁed Neu5Ac (compounds 3a and 3b) and C5-F, -OMe, or -
N3modiﬁed Kdn (compounds 7a–9a, 7b–9b) are not effectively cleaved
by any of the viral neuraminidases tested here. Among α2–6-linked
sialosides tested (compounds 1b–10b), only the ones containing
Neu5Ac or Neu5AcF (compounds 1b and 2b) are suitable but weak
substrates for the viral neuraminidases (Fig.S1).
Despite the similarities described above, the viruses showed
different neuraminidase activities to the modiﬁcations on the C-5
hydroxyl group of sialic acid in the sialoside substrates. For example,
α2–3-linked sialoside containing Neu5AcN3 (compound 4a), an/6GalβpNP containing different sialic acid forms (Cao et al., 2009) used for substrate
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Substrate speciﬁcities of neuraminidases on avian and human inﬂuenza viruses.
Type Viral strain Substrate speciﬁcityb
Comp. a Comp.b
a1a 2a 4a 5a 6a 10a 1b 2b
N1 sh/HKWF569/07 72 ++++ ++++ ++++ − − ++ +
sh/HKWF216/07 64 ++++ +++ ++++ − − − −
mal/8212/08 60 ++++ +++ ++++ − − + −
mal/8322/08 52 ++++ ++ +++ − − − −
tel8326/08 88 ++++ + ++++ − − +++ ++
N2 sh/HKWF268/07 59 ++++ + +++ − − ++ ++
tel/7972/08 40 +++ − +++ − − ++ +
N5 wi/HKWF295/07 41 ++++ ++ +++ − − + −
wi/HKWF541/07 71 ++++ +++ ++++ − + ++ +
wi/8352/08 34 ++++ +++ +++ − − + −
N6 dk/7896/08 28 ++++ + ++ − − ++ +
N7 emu/2092/96 32 ++++ − +++ + + ++ +
sh/JN950/06 57 ++++ + +++ + + ++ +
gos/HKWF446/07 88 ++++ +++ ++++ ++ +++ +++ +++
sh/HKWF848/07 88 ++++ +++ ++++ ++ ++ +++ ++
sh/HKWF1021/07 78 ++++ +++ ++++ + ++ ++ ++
sh/HKWF1128/07 46 ++++ ++ +++ + + ++ +
tel/HKWF1111/07 42 ++++ + ++ − + + +
mal/6957/08 81 ++++ + ++++ + + ++ ++
N8 dk/K90/05 72 ++++ + +++ − − − −
H9N2 avian dk/448/78 78 ++++ + +++ − − ++ ++
dk/702/79 76 ++++ ++ ++++ − + +++ ++
Q/29209-1/93 84 ++++ ++ ++++ − − +++ ++
pt/2373/98 73 ++++ − +++ − − ++ +
ck/SF3/99 69 ++++ − +++ − − ++ ++
QA23 37 ++++ − ++ − − + +
Qa23CkA10 37 ++++ − ++ − − + +
H9N2 Humanc HK/2108/03 32 ++++ − +++ − − +++ ++
Human unpuriﬁedc
N1 A/PR8 44 ++++ ++ +++ − − +++ ++
A/Mem71 35 ++++ ++ +++ − − +++ ++
N2 A/Udorn72 22 ++++ − +++ − − ++++ +++
A/Philips 34 ++++ − ++ − − +++ +++
Human puriﬁed N1c A/PR8 (puriﬁed) 84 ++++ ++ ++++ − − ++++ +++
A/Mem71(puriﬁed) 82 ++++ +++ ++++ − − +++ +++
a Absolute values for the percentage hydrolysis of Neu5Acα2-3GalβpNP(compound 1a) and relative value for all other compounds. Relative values: Virus neuraminidase activity
using Neu5Acα2–3GalβpNP (compound 1a) as the substrate is considered as 100%. “++++” represents activity ≥ 60%; “+++” represents activity ≥ 40% but b 60%; “++”
represents activity≥20% but b 40%;“+” represents activity≥10% but b 20%; “−“ represents activityb10%.
b The results for viruses with low activity [A405max is below 0.2 when Neu5Acα2–3GalβpNP (1a) is used as the substrate or the relative activity is below 10%]are not listed. These
include viruses mal/8035/08 (H5N2), tel/8204/08 (H5N9), Q/A28945/88 (H9N2), dk/Y280/97 (H9N2), and ck/G9/97 (H9N2).
c Human inﬂuenza A viruses are shown in italics. Underlined are group 1 NA viral strains. Others are group 2 NA viral strains.
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idases tested (N1, N5, most N7, and some N2) but not others (most
N2, some N7, and N9). Many N7-expressing inﬂuenza A viruses
cleaved α2–3-linked sialosides containing either Kdn (compoundTable 4
IC50s of Zanamivir and NeuAc2en for activities of human and inﬂuenza A virus neuraminid
Viral Strain Type IC50
Neu5Acα2–3GalβpNP
Zanamivir (nM)
sh/HKWF569/07 H3N1 14.3±1.6
mal/8212/08 H6N1 6.5±0.3
wi/HKWF541/07 H6N5 17.2±2.8
sh/JN950/06 H10N7 10.4±1.4
gos/HKWF446/07 H10N7 23.6±2.7
mal/6957/08 H10N7 49.9±3.1
Q/29209-1/93 H9N2 59.9±3.6
ck/SF3/99 H9N2 20.3±1.3
Qa23CkA10 H9N2 9.5±1.6
A/PR8b H1N1 3.3±0.2
A/Udorn72b H3N2 94.4±6.2
a Unpuriﬁed avian inﬂuenza A viruses (12.8 HAU mL−1) and puriﬁed human viruses (A
carried out at 37 °C for 60 min with 1 mM of substrate.
b Puriﬁed human inﬂuenza A virus; ND, not determined.10a) or its 5-deoxy derivative (5d-Kdn) (compound 6a), a unique
substrate speciﬁcity not shared by the other strains tested.
H9N2 avian inﬂuenza A viruses continue to circulate worldwide. In
Asia, H9N2 viruses have caused disease outbreaks and establishedases.a
Neu5Acα2–6GalβpNP
Neu5Ac2en (μM) Zanamivir (nM) Neu5Ac2en (μM)
10.7±1.4 ND ND
3.8±0.4 ND ND
1.8±0.5 ND ND
5.0±1.3 ND ND
7.9±1.4 ND ND
23.2±1.5 ND ND
48.3±5.8 12.8±1.0 7.2±1.3
6.7±0.8 ND ND
6.4±1.2 ND ND
2.6±0.5 3.2±0.5 1.8±0.4
17.8±4.7 78.8±6.8 11.3±2.7
/PR8, 1×104 HAU mL−1; A/Udon, 5×103 HAU mL−1) were used. The reactions were
Table 5
Percentage inhibition of Neu5Gc2en, Neu5AcN32en, and Kdn2en against inﬂuenza A virus neuraminidases using Neu5Acα2–3GalβpNP or Neu5Acα2–6GalβpNP as the substrate.a
Viral Strain Type % inhibition with Neu5Acα2–3GalβpNP as the substrate
Neu5Gc2en Neu5AcN32en Kdn2enb
100 μM 500 μM 1 mM 1 mM 5 mM 10 mM 10 mM
sh/HKWF569/07 H3N1 24.1±5.6 56.3±0.7 72.9±0.3 27.6±0.3 51.9±0.1 61.6±1.3 7.5±0.4
mal/8212/08 H6N1 40.2±1.9 78.4±1.0 87.3±0.6 39.1±1.2 72.9±1.0 80.5±0.2 22.9±1.7
wi/HKWF541/07 H6N5 14.9±2.1 53.9±1.5 71.7±0.1 29.3±1.9 66.3±1.7 77.1±0.3 10.7±2.5
sh/JN950/06 H10N7 42.2±0.5 81.0±1.2 90.9±0.4 29.9±0.6 65.7±0.7 73.5±1.2 45.9±0.4
gos/HKWF446/07 H10N7 29.1±0.7 66.3±4.1 82.7±1.8 26.8±0.6 53.2±0.8 65.4±0.2 40.5±1.3
mal/6957/08 H10N7 14.3±2.0 51.6±1.5 71.9±0.2 8.6±0.4 34.2±0.4 52.2±2.0 18.8±0.9
Q/29209-1/93 H9N2 6.1±0.2 29.5±4.6 53.9±0.4 6.7±0.1 23.2±0.7 36.0±1.7 –
ck/SF3/99 H9N2 36.1±0.9 77.4±0.3 87.7±0.2 30.1±0.6 67.5±1.1 79.0±0.2 13.1±0.1
Qa23CkA10 H9N2 37.6±0.6 76.4±0.9 85.9±0.3 23.3±0.9 63.0±0.1 72.1±1.6 –
A/PR8c H1N1 48.5±2.2 84.6±0.2 90.4±0.2 66.7±0.5 88.9±0.9 90.1±0.4 42.2±2.4
A/Udorn72c H3N2 18.1±0.2 42.3±0.3 57.6±2.0 – – 10.0±0.6 –
% inhibition with Neu5Acα2–6GalβpNP as the substrate
Q/29209-1/93 H9N2 39.4±0.5 80.2±1.27 90.5±0.4 23.8±2.2 57.3±0.3 64.2±1.4 –
A/PR8c H1N1 54.5±1.3 80.9±0.8 86.6±0.5 66.9±3.0 82.2±1.1 82.0±0.3 43.5±0.5
A/Udorn72c H3N2 24.4±0.3 61.7±0.3 73.6±0.3 – 24.4±0.8 43.5±2.4 –
“−”, no inhibition.
a Unpuriﬁed avian inﬂuenza A viruses (12.8 HAUmL−1) and puriﬁed human viruses (A/PR8, 1×104 HAUmL−1; A/Udorn72, 5×103 HAUmL−1; A/Mem71, 5×103 HAUmL−1; A/
Philips: 2×104 HAU mL−1) were used. The reactions were carried out at 37 °C for 60 min with 1 mM of substrate.
b Kdn2en did not show any inhibition against the neuraminidase activity of A/Mem71 and A/Philips.
c Puriﬁed human inﬂuenza A virus.
16 Y. Li et al. / Virology 415 (2011) 12–19lineages in land-based poultry (Aamir et al., 2007; Alexander, 2007;
Guo et al., 1999; Kim et al., 2006; Naeem et al., 1999; Nili and Asasi,
2003). Importantly, H9N2 viruses have occasionally transmitted from
land-based poultry to mammals, including humans. Mild respiratory
diseases of humans were reported in Hong Kong and mainland China
in 1999 and again in Hong Kong in 2003 (Butt et al., 2005; Lin et al.,
2000; Peiris et al., 2001). We analyzed a series of H9N2 inﬂuenza A
viruses isolated from ducks, quail, chicken, pheasant, and humans in
Hong Kong over a period of 25 years (1978–2003) and two laboratory-
adapted viruses (QA23 and Qa23CkA10) (Table 1). This provided an
excellent opportunity to correlate possible changes of neuraminidase
substrate speciﬁcity with interspecies transmission and avian to
human adaptation (Wan et al., 2008). Similar to other N2 inﬂuenza
A viruses (Fig. S1B), α2–3- and α2–6-linked sialosides containing
Neu5Ac or Neu5AcF (compounds 1a, 1b, 2a, and 2b), andα2–3-linked
sialoside containing Neu5Gc (compound 5a) were proven to be good
substrates. However, the α2–3-linked sialoside containing Neu5AcN3
(compound 4a) was a weak substrate for some N2 strains such as dk/
702/79 and Q/29209-1/93 (Fig. S1F) but not a substrate for others. No
other compounds were substrates for these viruses. Signiﬁcantly,
there were noticeable differences between the overall sialidase
activity and the relative ratio of α2–6-sialidase versus α2–3-sialidase
activities among H9N2 strains isolated from different species and
different times. The laboratory adapted H9N2 viruses showed lower
relative α2–6-sialidase activity while the human H9N2 virus showed
higher relative α2–6-sialidase activity (Fig. S1F).
Substrate speciﬁcities of neuraminidases from human inﬂuenza A viruses
A similar pattern of substrate speciﬁcity was observed for both
sucrose-gradient-puriﬁed (Fig. S2A) and non-puriﬁed human inﬂuenza
A viruses (Fig. S2B) (Table 3). The latter were used in form of virus-
containingallantoicﬂuid. Thepuriﬁcationprocessdid, however, seemto
decrease the neuraminidase activity of the puriﬁed viruses, requiring
the use of higher viral amounts in the assays. Similar to the avian
inﬂuenza A viruses tested, the neuraminidases from human viruses
cleavedα2–3-linked sialosideswith higher efﬁciency thanα2–6-linked
sialosides. All four human viruses cleaved Neu5Ac and Neu5AcF
efﬁciently from α2–3- and α2–6-linked sialosides (compounds 1a, 1b,
2a, and 2b). α2–3-Linked sialoside containing Neu5Gc (compound 5a)
is also a suitable substrate for thesehumanvirus strains. In contrast,α2–3-linked sialoside containing Neu5AcN3 (Neu5AcN3α2–3GalβpNP,
compounds 4a) is a suitable substrate for A/PR8 and A/Mem71 (N1
type), but not for either A/Udorn72 or A/Philippines (N2 type). This
result was consistent with the NA activity of avian inﬂuenza A viruses
described above. The human inﬂuenza A viruses tested were unable to
cleave α2–3/6-linked sialosides containing Neu5AcOMe, Kdn, or Kdn
derivatives (compounds 3a, 3b, 6a–10a, and 6b–10b). Overall, the sialic
acid hydrolysis activities of human inﬂuenza A viruses were lower than
those of avian inﬂuenza strains, as higher titers of human viruses (500–
10,000 HAU mL−1) had to be used to achieve similar hydrolysis
efﬁciency to avian viruses (12.8 HAU mL−1).
Inhibition studies of viral neuraminidases
A sialidase transition state analog, Neu5Ac2en, is a nonselective
inhibitor against sialidases, including inﬂuenza A virus NAs. To test
the inhibitory activity of the non-selective inhibitor Neu5Ac2en, we
synthesized it and its C5-derivatives Neu5Ac2en derivatives 2-deoxy-
2,3-dehydro-N-glycolylneuraminic acid (Neu5Gc2en), 2-deoxy-2,3-
dehydro-N-azidoacetylneuraminic acid (Neu5AcN32en), and 2-
deoxy-2,3-dehydro-Kdn (Kdn2en) (Li et al., 2011). These compounds
were tested against NAs from different viruses, using a microtiter-
plate based inhibition assay (Li et al., 2011) and their activities were
compared to that of a commercially available inﬂuenza A virus NA
inhibitor Zanamivir (a C4-guanadino derivative of Neu5Ac2en). As
shown in Table 4, when Neu5Acα2–3GalβpNP (compound 1a) was
used as the neuraminidase substrate for the inhibition assays, the
IC50s of Neu5Ac2en were in the range of 2.6–48.3 μM for nine avian
inﬂuenza A viruses with four NA subtypes and two human inﬂuenza A
viruses with different NA subtypes. The inhibitory activity of
Neu5Ac2en was the least efﬁcient for avian inﬂuenza A viruses Q/
29209-1/93 (IC50=48.3±5.8 μM) and mal/6957/08 (IC50=23.2±
1.5 μM) and most efﬁcient for avian inﬂuenza A viruses mal/8212/08
(IC50=3.8±0.4 μM) and wi/HKWF541/07 (IC50=1.8±0.5 μM), as
well as human A/PR8 (IC50=2.6±0.5 μM). In comparison, commer-
cial inﬂuenza virus speciﬁc inhibitor Zanamivir has IC50s in a range of
3.3–94.4 nM, indicating that Zanamivir is about three orders of
magnitude more efﬁcient than Neu5Ac2en. The Neu5Ac cleavage
activities of Neu5Acα2–3GalβpNP by neuraminidases of human
virus A/PR8 (IC50=3.3±0.2 nM) and avian viruses mal/8212/08
(IC50=6.5±0.3 nM) and Qa23CkA10 (IC50=9.5±1.6 nM) were
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especially avian viruses Q/29209-1/93 (IC50=59.9±3.6 nM) and
mal/6957/08 (IC50=49.9±3.1 nM) as well as human virus A/
Udorn72 (IC50=94.4±6.2 nM). When Neu5Acα2–6GalβpNP (com-
pound 1b) was used as the neuraminidase substrate for some viruses
which have signiﬁcantα2–6-sialidase activity, the IC50s of Neu5Ac2en
were in sub micromolar range (1.8–11.3 μM) and those of Zanamivir
were in the range of 3.2–78.8 nM.
Because of the differences of virus NAs in their effectiveness of
cleaving sialosides containing different C5-modiﬁed sialic acids, we
hypothesized that C5-derivatives of the nonselective sialidase
inhibitor Neu5Ac2en might act as selective inhibitors against NAs of
certain inﬂuenza A strains. To test this hypothesis, the inhibitory
activities of three C5-analogs of Neu5Ac2en: Neu5Gc2en, Neu5AcN32-
en, and Kdn2en were tested against nine non-puriﬁed avian inﬂuenza
A viruses and the two puriﬁed human inﬂuenza A viruses. As shown in
Table 5, these three compounds were less potent inhibitors compared
to Neu5Ac2en. Except for A/PR8whose IC50 of Neu5Gc2enwas around
100 μM, the IC50s of Neu5Gc2en for the other virus NAswere N100 μM.
Furthermore, for all virus NAs tested, the IC50s of Neu5AcN32en
wereN1 mM and those of Kdn2en wereN10 mM. The higher IC50
values obtained for Neu5Gc2en (IC50N100 μM), Neu5AcN32en
(IC50N1 mM), and especially Kdn2en (IC50N10 mM) agreed well
with the observation that sialosides containing Neu5Gc, Neu5AcN3,
and Kdn were less efﬁcient substrates than Neu5Ac-containing
sialosides for inﬂuenza A viruses tested here (Fig. S1 and Fig. S2).
Discussion
Avian inﬂuenza A virus NAs have relatively high activity and
exhibit substrate preference for α2–3-sialylated glycan substrates,
while human virus NAs have lower activity and cleave bothα2–3- and
α2–6-sialylated glycans. Preferences between avian and human NAs
differ also for the internal glycan structures of the sialoside substrates
(Shtyrya et al., 2009). The binding of HAs (i.e. ligand speciﬁcity) to
host cells needs to match the activity of NAs (i.e. substrate speciﬁcity)
to achieve efﬁcient viral infection and replication (Mitnaul et al.,
2000; Shtyrya et al., 2009; Wagner et al., 2000). Despite the existence
of more than 50 different natural sialic acid forms (Angata and Varki,
2002; Chen and Varki, 2010; Schauer, 2000), little information exists
about the ligand preferences of HAs, or the substrate speciﬁcities of
NAs on human and avian inﬂuenza A viruses with regard to the
terminal sialic acid structures of sialosides.
Some similarities were identiﬁed among the NAs of all tested avian
andhuman inﬂuenzaAviruses. First,α2–3-linked sialosideswere better
substrates than α2–6-linked sialosides. Second, among 20 sialyl
galactosides tested, Neu5Acα2–3GalβpNP (compound 1a) containing
the most abundant sialic acid form, Neu5Ac, was the best substrate
for all virus NAs. Third, substitution of one of the three hydrogen atoms
by a ﬂuorine atom on the N-acetyl group of Neu5Ac-terminated
sialosides did not signiﬁcantly decrease the activities of virus NAs,
indicating the similarity betweena hydrogen andﬂuorine. This property
is very similar to that observed for human and bacterial sialidases (Cao
et al., 2009; Li et al., 2011). Fourth, α2–3-linked sialoside containing
a non-human sialic acid form, Neu5Gc, was a suitable substrate for
all human and avian inﬂuenza A virus NAs tested, despite the lack of
such monosaccharide at the site of host infection.
Despite these similarities, obvious differences existed between the
degrees of substrate preference between the tested viral NAs for α2–
6-linked sialosides versus α2–3-linked sialosides. Furthermore, N7
subtype NAs had distinct subtype speciﬁcities. They were the only
viral NAs that used α2–3-linked sialoside substrates containing Kdn
(compound 6a) or 5-deoxy-Kdn (5d-Kdn, compound 10a).
Our detailed analysis of the substrate speciﬁcity of 27 different
inﬂuenza A virus NAs revealed that their relative preference for α2–3-
linked sialoside substrates differed between host origin and time ofisolation (Table S1). Although the ratios of relative neuraminidase
activities on Neu5Acα2–6GalβpNP (compound 1b) versus Neu5Acα2–
3GalβpNP (compound 1a) substrates were all below 1, they varied from
low, such as for avian inﬂuenza A viruses sh/HKWF216/07 (H6N1, 0.09),
mal/8322/08 (H6N1, 0.09), and dk/K90/05 (H6N8, 0.06), to high, as for
human inﬂuenza A virus A/Udorn72 (H3N2, 0.64) and three other
human viruses (1b/1a ratioN0.4). In contrast to human inﬂuenza viral
NAs, the ratios of activities on Neu5Acα2–6GalβpNP (compound 1b)
versus Neu5Acα2–3GalβpNP (compound 1a) substrateswere relatively
low formost NAs of avian inﬂuenza A viruses except for gos/HKWF446/
07 (H10N7, 0.57), dk/702/79 (H9N2, 0.43), Q/29209-1/93 (H9N2, 0.49),
ck/G9/97 (H9N2, 0.48). These results were consistent with previous
studies demonstrating that Neu5Acα2–3Gal was a preferred substrate
over Neu5Acα2–6Gal for avian, swine, and N2 human inﬂuenza A
viruses (Kobasa et al., 1999).
Based on their three-dimensional structures, neuraminidases from
nine NA subtypes can be separated into two groups: Group 1 NA viral
strains containing N1, N4, N5, and N8 subtypes and group 2 NA strains
containing N2, N3, N6, N7, and N9 subtypes (Russell et al., 2006a). The
major structural difference between group 1 and group 2 is a cavity
observed in the active site close to ligand binding site of group 1 NAs,
which is absent in the group 2 NAs (Russell et al., 2006a). Therefore,
substrates for group 1 NAs might not be hydrolyzed by group 2 NAs.
Based on their structural similarities, NAs in group 1 might have
similar substrate speciﬁcities, and differ from those shared by group 2
NAs. Indeed, the substrate speciﬁcities of groups 1 and 2 NAs revealed
distinct patterns. As shown in Table 3, group 1 NAs have good
cleavage activity against α2–3-linked sialosides containing Neu5AcF
(compound 2a), Neu5AcN3 (compound 4a), and Neu5Gc (compound
5a), as well as Neu5Acα2–3GalβpNP (compound 1a). In contrast,
group 2 NAs have good activity towards α2–3-linked sialosides
containing Neu5AcF (compound 2a), and Neu5Gc (compound 5a) as
well as Neu5Acα2–3GalβpNP (compound 1a). However, Neu5AcN3-
α2–3GalβpNP (compound 4a) is not a good substrate for most group
2 NAs, except for most N7 subtype strains and some belonging to the
H9N2 subtype.
We demonstrate here that using a high-throughput approach to
screen a library of para-nitrophenol-tagged α2–3- and α2–6-linked
sialosides Siaα2–3/6GalβpNP is a highly effective means to conduct
substrate speciﬁcity studies of sialidases frommany inﬂuenza viruses.
The neuraminidases of non-puriﬁed inﬂuenza A viruses share the
same substrate speciﬁcity pattern as those from puriﬁed viral
particles. Therefore, non-puriﬁed inﬂuenza A viruses can be directly
used for substrate speciﬁcity assays, saving on labor and time-
consuming viral isolation procedures and preventing the activity loss
of NAs observed during the viral particle puriﬁcation process. In
addition, the inhibitory activity of two know NA inhibitors, Zanamivir
and Neu5Ac2en, and three new candidate inhibitors, Neu5Gc2en,
Neu5AcN32en and Kdn2en, were efﬁciently characterized using
Neu5Acα2–3/6GalβpNP as substrate for viral NAs. These high-
throughput substrate speciﬁcity and inhibition assays are much
more efﬁcient than the reported assays using peroxidase-linked lectin
or ﬂuorescence detection coupled with separation by an anion-
exchange microcartridge (Mochalova et al., 2005) or a DEAE ﬁlter
(Mochalova et al., 2007). The knowledge gained about the substrate
speciﬁcity of individual inﬂuenza strains utilizing these rapid assays
allows for the design of inhibitors that selectively target a distinct
group of inﬂuenza A virus NAs.
Materials and methods
Viruses
Thirty-seven avian and human inﬂuenza A virus strainswere used
in this study (Table 1). Unless indicated otherwise, the avian viruses
were provided by the Cardona group and were collected through
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Inﬂuenza Research and Surveillance or Avian Inﬂuenza Coordinated
Agricultural projects (A/northern shoveler/California/JN950/2006).
A/emu/California/2092/1996 and A/pheasant/California/2373/1998
were fromdiagnostic cases submitted to the California Animal Health
and Food Safety Laboratory. A human H9N2 virus preparation (A/
Hong Kong/2108/2003) was provided by Dr. Yi Guan at the
University of Hong Kong. All avian H9N2 subtype viruses excluding
A/pheasand/California/2373/1998 were from Dr. Daniel Perez.
Among H9N2 avian inﬂuenza A viruses, QA23 and Qa23CkA10
viruses are laboratory-adapted viruses. QA23 virus was developed
by adapting a wild type duck H9N2 viral isolate, inﬂuenza dk/702/79
virus, in quail through 23 serial lung passages, and the chicken-
adapted QA23CkA10 virus was obtained from the 10th chicken lung
passage of the QA23 virus (Hossain et al., 2008). Allantoic-ﬂuid
containing the virus strains were used for the assays.
Among the strains used, four were human inﬂuenza A viruses (A/
Puerto Rico/34/8, H1N1; A/Memphis71, H3N1; A/Udorn/307/72,
H3N2; and A/Philippines/2/82/X-79, H3N2). A/Memphis71 is a
reassortant inﬂuenza A virus strain carrying the hemagglutinin of A/
Memphis/1/71 (H3) and the neuraminidase of A/Bellamy/42 (N1). All
four human inﬂuenza A viruses used were propagated from frozen
stocks originally obtained from Lorena Brown (University of Mel-
bourne, Australia) and Charles Stephensen (UC Davis). Both sucrose-
gradient puriﬁed virus particles and allantoic-ﬂuid containing the
human virus strains were used for the assays to test the effect of
potential contaminating proteins in the allantoic ﬂuid and/or the
effects of the virus puriﬁcation procedures on the activity and
substrate speciﬁcity of viruses.Virus propagation
Avian virus isolates were passaged by inoculation into 9–11 days
speciﬁc-pathogen-free (SPF) embryonating chicken eggs (SPAFAS,
Charles River) following standard methods (WHO, 2002). Allantoic
ﬂuid samples were tested for hemagglutination using 0.5% chicken
blood (Colorado Serum Company, Denver, CO) as described previously
(Li et al., 2008; WHO, 2002).
For human virus, fertilized hen eggs were incubated for 10 days
with constant rotation at 37°C and 65% humidity. Eggs containing
live embryos were infected with predetermined optimal concentra-
tions of inﬂuenza virus strains by inoculation into the allantoic cavity
and incubated for 2 days at 35 °C followed by overnight incubation at
4 °C. Allantoic ﬂuid was harvested, batched, and centrifuged (8000g,
15 min at 4 °C). Supernatants were aliquoted, snap-frozen on dry ice
and stored at −80 °C until used.Puriﬁcation of human inﬂuenza A virus
For virus puriﬁcation, batches of allantoic ﬂuid from infected eggs
were centrifuged. Virus particles were precipitated from supernatants
by overnight incubation at 4 °C with 8% polyethylene glycol 6000
solution (Sigma-Aldrich, Dallas, TX) and pelleted by centrifugation
(12,000g, 30 min at 4 °C). To release the virus, the pellet was resus-
pended in phosphate buffered saline (PBS), sonicated, and centrifuged
for 5 min at 3000g. The supernatant was collected and centrifuged
(24,000g, 2 h at 4 °C). The virus pellets were resuspended in a small
volumeof PBS and separatedby sucrose gradient centrifugation (linear
gradient 70–25%, 24,000g, 2 h at 4 °C). The virus band was harvested,
resuspended in PBS and centrifuged (24,000g, 2 h at 4 °C). The pellet
containing the virus was stored in a small volume of PBS at 4 °C. The
virus concentration (HAU/mL) was determined by standard hemag-
glutination assays using chicken red blood cells (Li et al., 2008; WHO,
2002).Sialosides and neuraminidase inhibitors
The sialosides used in this study were synthesized using a one-pot
three-enzyme approach as described previously (Cao et al., 2009).
Zanamivir was from TCI America Ltd. (Portland, OR). Neuraminidase
inhibitors 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (Neu5A-
c2en), 2-deoxy-2,3-dehydro-N-glycolylneuraminic acid (Neu5Gc2en),
2-deoxy-2,3-dehydro-N-azidoacetylneuraminic acid (Neu5AcN32en),
and 2-deoxy-2,3-dehydro-Kdn (Kdn2en) were synthesized using a
chemoenzymatic method as reported (Li et al., 2011).
Sialidase substrate speciﬁcity assays
Twenty sialyl galactosides including Siaα2–3/6GalβpNP contain-
ing N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid
(Neu5Gc), 2‐keto‐3‐deoxy‐D-glycero-D-galacto-nonulosonic acid
(Kdn), or their C5-derivatives (Table 2) (Cao et al., 2009) were used
to study the substrate speciﬁcity of neuraminidases on thirty-seven
inﬂuenza A viruses using a microtiter plate-based high-throughput
colorimetric assay method (Cao et al., 2009; Chokhawala et al., 2007).
All sialidase assays were carried out at 37 °C in duplicate in 384-well
plates (Fisher Scientiﬁc, Chicago, IL) in a ﬁnal volume of 20 μL each
containing MES buffer (100 mM, pH 5.0), a certain titer of allantoic
ﬂuid containing virus or sucrose-puriﬁed viral particles, a sialoside
substrate (0.3 mM), and an Aspergillus oryzae β-galactosidase (12 μg,
126 mU) from Sigma (St. Louis, MO). The amount of the β-
galactosidase required to completely hydrolyze the GalβpNP within
the time frame of the assay was pre-determined and conﬁrmed by
control assays with GalβpNP (0.3 mM). The reactions were carried out
for 60 min and were stopped by adding pre-chilled CAPS buffer (N-
cyclohexyl-3-aminopropane sulfonic acid, 40 μL, 0.5 M, pH 10.5). The
amount of the para-nitrophenolate formed was determined by
measuring the A405 nm of the reaction mixtures using a microtiter
plate reader. As described before (Cao et al., 2009; Chokhawala et al.
2007), if a sialoside is the substrate of the neuraminidase of the
virus tested, the sialic acid on the sialoside will be cleaved off by
the neuraminidase to provide GalβpNP, which is quickly hydrolyzed
by the excess amount of β-galactosidase in the reaction mixture to
give para-nitrophenol. Addition of the pre-chilled CAPS buffer at
the end of the incubation converts most of the para-nitrophenol to
para-nitrophenolate whose concentration can be determined by
measuring its absorption at 405 nm. The A405 nm reading is propor-
tional to the amount of the sialic acid released from the sialoside
by the neuraminidase of the virus and can be used to compare the
substrate speciﬁcity of different neuraminidases on the surface of
different viral strains.
Inhibition assay of viral neuraminidases
Inhibition assays were carried out in duplicate in 384-well plates
in a total volume of 20 μL each in MES buffer (100 mM, pH 5.0) similar
to that described above for the sialidase substrate speciﬁcity assays
except that a ﬁxed concentration of Neu5Acα2–3GalβpNP or
Neu5Acα2–6GalβpNP (1 mM)was used as the substrate and different
concentrations of sialidase inhibitors were used. To determine IC50
values for Zanamivir and Neu5Ac2en, at least 11 different concentra-
tions varying from 0 to 10.0 mMwere used. IC50 values were obtained
using Graﬁt 5.0 for logarithm concentration-response plots. When
Neu5Gc2en (100 μM, 500 μM, and 1 mM), Neu5AcN32en (1 mM,
5 mM, and 10 mM), or Kdn2en (10 mM) was used as an inhibitor,
only certain concentrations were chosen.
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